Research focus
About the research
Can fragment-based methods and structure-based design be used to find drugs for hard-to-drug cancer targets?
Read the full research overview
Stephen Fesik is a Professor of Biochemistry, Pharmacology and Chemistry who holds the Orrin H. Ingram II Chair in Cancer Research. The Fesik lab uses fragment-based methods to identify small molecules, called fragments, that bind to difficult targets and structure-based design to optimize them for binding to the target protein. Current projects include discovery of KRAS inhibitors, WDR5 inhibitors and MYC/MAX inhibitors. The lab also works on the development of new NMR methods for fragment screening.
Selected publications
3 listedFragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS G12C Inhibitor
Journal of Medicinal Chemistry
Impact of WIN site inhibitor on the WDR5 interactome
Cell Reports
The BCL-2 protein family: from discovery to drug development
Cell Death and Differentiation
People & alumni
Team details haven’t been added. See the lab’s website for its current members.
Alumni details haven’t been added. Check the lab’s official website.
Sources & listing information
Find Research Labs maintains this page using public sources. The faculty member, lab, and university have not claimed or approved this listing. Listing a lab does not indicate endorsement, partnership, or a recruiting opportunity.
Request a correction or removal ↗ · About directory listings